Loading…
Employees: 3,200
Size WELL Health Technologies (WELL.TO) is a Canada Health Care company (Medical/Nursing Services) with a market value of $760M, the 286th largest of 420 Canada companies the cockpit tracks. Shares closed at C$4.16 on 6 Nov 2026.
Performance Over six months the shares fell 4.8%, against +1.3% for the median peer and +5.2% for the Canada market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue grew 38.5% over the last twelve months (peer median +6.9%); the operating margin is 7.4% (peer median 7.7%).
Valuation It trades at 14.7× forward earnings against a peer median of 24.0× (6th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +95%, so the hurdle is -85 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.0 points below its cost of capital (7.3% WACC).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | C$1.52B | C$1.40B | C$920M | C$776M | C$569M |
| Revenue growth | — | +52% | +19% | +36% | — |
| Gross profit | C$582M | C$525M | C$291M | C$311M | C$248M |
| EBITDA | C$215M | C$207M | C$52.9M | C$102M | C$81.7M |
| Net income | C$3.77M | -C$7.36M | C$32.6M | C$82,000 | C$1.37M |
| Free cash flow | C$81.8M | C$87.9M | -C$10.6M | C$37.2M | C$65.7M |
| Capital expenditure | C$39.0M | C$27.9M | C$16.2M | C$25.4M | C$6.62M |
| Total debt | C$953M | C$711M | C$473M | C$426M | C$358M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | WELL.TO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.6% | -1.1% | 10th lowest of 21 |
| 6-month return | -4.8% | +1.3% | 6th lowest of 20 |
| Distance from 52-week high | -19.9% | -22.6% | 8th highest of 21 |
| Revenue growth (TTM) | +38.5% | +6.9% | 2nd highest of 21 |
| Operating margin | 7.4% | 7.7% | 11th highest of 21 |
| Forward P/E | 14.7× | 24.0× | 6th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 9.1% | 11.7% | 9th least demanding of 17 |
| Growth delivered (Del g) | +94.5% | +11.5% | 2nd highest of 17 |
| Hurdle (Req g minus delivered) | -85.5 pp | -0.3 pp | 2nd least demanding of 17 |
| ROIC minus cost of capital | -3.0 pp | -1.0 pp | 8th lowest of 20 |
| EV / EBITDA | 9.6× | 8.4× | 7th most expensive of 14 |
| Net debt / EBITDA | 3.8× | 0.8× | 3rd most indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| WELL Health Technologies WELL.TO | Canada | $760M | -5% | +39% | 7% | 14.7× | 9.1% | +94.5% |
| Ginkgo Bioworks DNA | United States | $760M | +26% | -52% | -258% | n/a | n/a | n/a |
| HK inno.N 195940.KS | South Korea | $745M | -32% | +7% | 12% | 11.8× | -10.8% | +12.2% |
| Jinxin Fertility 1951.HK | Hong Kong | $800M | -2% | +7% | 11% | 24.4× | 18.0% | +12.4% |
| Thyrocare Technologies THYROCARE.NS | India | $830M | +5% | +22% | 26% | 35.2× | 27.9% | +10.9% |
| GMR Solutions GMRS | United States | $672M | n/a | -4% | 14% | 8.0× | -20.0% | -4.0% |
| Terveystalo Oy TTALO.HE | Finland | $883M | -19% | -8% | 8% | 11.1× | -4.6% | +5.3% |
| Fulgent Genetics FLGT | United States | $653M | +49% | +7% | -36% | n/a | n/a | n/a |
| BML 4694.T | Japan | $887M | -2% | +4% | 7% | 18.6× | -9.7% | +1.6% |
| Nephrocare Health Services NEPHROPLUS.NS | India | $639M | +10% | +33% | 14% | 41.9× | 35.7% | +31.6% |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $593M | -4% | -19% | 6% | n/a | 8.8% | +3.2% |
| AdaptHealth AHCO | United States | $1.00B | +8% | -3% | 3% | n/a | 16.3% | +25.2% |
| Regis Healthcare REG.AX | Australia | $1.05B | -17% | +17% | 4% | 25.1× | 14.6% | +14.4% |
| Novogene 688315.SS | China | $1.16B | +31% | +6% | 7% | 35.7× | 17.1% | +8.2% |
| Strata Critical Medical SRTA | United States | $497M | 0% | +23% | -4% | 67.4× | n/a | n/a |
| GoodRx GDRX | United States | $1.20B | +20% | -2% | 12% | 10.4× | 6.8% | +7.7% |
| JS Link 127120.KS | South Korea | $481M | -57% | +51% | -76% | n/a | n/a | n/a |
| Nutex Health NUTX | United States | $1.24B | +32% | +7% | 43% | 7.2× | -19.5% | +253.5% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +12% | +20% | 18% | 45.6× | 32.4% | +10.5% |
| Pennant PNTG | United States | $1.27B | +1% | +38% | 6% | 24.0× | 21.1% | +19.4% |
| Integral Diagnostics IDX.AX | Australia | $450M | -21% | +26% | 9% | 15.5× | 8.3% | +17.7% |